The Insulin-like Growth Factor Binding Proteins (IGFBPs) in Human Breast Cancer

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 1992 Jan 1

PMID 1384805

Citations 9

Authors

J A Figueroa

D Yee

Affiliations

Soon will be listed here.

Abstract

Several lines of evidence suggest that IGFs are important regulators of breast cancer cell growth. Unlike other growth factors, the IGFs interact with specific binding proteins in all extracellular fluids. To date, six different IGFBPs have been cloned, although their exact physiological function is not understood. Experimental evidence accumulated over the past few years suggests that IGFBPs could function as modulators of IGF actions in a variety of systems. This includes breast cancer, since several groups have demonstrated the production of IGFBPs by human breast cancer cells. We have found that the pattern of expression of these binding proteins is heterogeneous and varies depending on the breast cancer cell ER status. We have also shown that estrogen is capable of regulating the expression of certain IGFBPs in MCF-7 cells. Specifically, estradiol enhanced the expression of IGFBP 2, 4, and 5, and decreased that of IGFBP-3 in this cell line. Since the IGFBPs can modulate IGF actions in different experimental systems, we and others have studied their potential role as inhibitors of IGF-induced mitogenesis in breast cancer cells. We have demonstrated that purified IGFBP-1 neutralized IGF-dependent growth of MCF-7 cells in a reversible manner. These results suggest that the IGFBPs might be used to inhibit IGF-mediated breast cancer proliferation.

Citing Articles

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.

Foekens J, Diamandis E, Yu H, Look M, Meijer-van Gelder M, van Putten W Br J Cancer. 1999; 79(5-6):888-94.

PMID: 10070886 PMC: 2362687. DOI: 10.1038/sj.bjc.6690142.

Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

Favoni R, DE CUPIS A, Bruno S, Yee D, Ferrera A, Pirani P Br J Cancer. 1998; 77(12):2138-47.

PMID: 9649125 PMC: 2150424. DOI: 10.1038/bjc.1998.358.

Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer.

Yu H, Levesque M, Khosravi M, Clark G, Diamandis E Br J Cancer. 1996; 74(8):1242-7.

PMID: 8883411 PMC: 2075943. DOI: 10.1038/bjc.1996.523.

Postsynthetic regulation of insulin-like growth factor-binding protein-3 by MCF-7 human breast cancer cells in culture.

Grimes R, Manni A, Hammond J Breast Cancer Res Treat. 1996; 39(2):187-96.

PMID: 8872327 DOI: 10.1007/BF01806185.

Activation of the E-cadherin/catenin complex in human MCF-7 breast cancer cells by all-trans-retinoic acid.

Vermeulen S, Bruyneel E, van Roy F, Mareel M, Bracke M Br J Cancer. 1995; 72(6):1447-53.

PMID: 8519658 PMC: 2034086. DOI: 10.1038/bjc.1995.528.

References

DE LEON D, Bakker B, Wilson D, Hintz R, Rosenfeld R . Demonstration of insulin-like growth factor (IGF-I and -II) receptors and binding protein in human breast cancer cell lines. Biochem Biophys Res Commun. 1988; 152(1):398-405. DOI: 10.1016/s0006-291x(88)80727-7. View

Daly R, Harris W, Wang D, Darbre P . Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ. 1991; 2(9):457-64. View

Herington A, Kuffer A . Identification of a specific inhibitor of nonsuppressible insulin-like activity in a partially purified human serum fraction. Endocrinology. 1981; 109(5):1634-40. DOI: 10.1210/endo-109-5-1634. View

Kim I, Manni A, Lynch J, Hammond J . Identification and regulation of insulin-like growth factor binding proteins produced by hormone-dependent and -independent human breast cancer cell lines. Mol Cell Endocrinol. 1991; 78(1-2):71-8. DOI: 10.1016/0303-7207(91)90187-w. View

Brewer M, Stetler G, Squires C, Thompson R, Busby W, Clemmons D . Cloning, characterization, and expression of a human insulin-like growth factor binding protein. Biochem Biophys Res Commun. 1988; 152(3):1289-97. DOI: 10.1016/s0006-291x(88)80425-x. View

Knauer D, Smith G . Inhibition of biological activity of multiplication-stimulating activity by binding to its carrier protein. Proc Natl Acad Sci U S A. 1980; 77(12):7252-6. PMC: 350480. DOI: 10.1073/pnas.77.12.7252. View

Liu L, Brinkman A, Blat C, Harel L . IGFBP-1, an insulin like growth factor binding protein, is a cell growth inhibitor. Biochem Biophys Res Commun. 1991; 174(2):673-9. DOI: 10.1016/0006-291x(91)91470-w. View

Fraker L, Halter S, Forbes J . Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. Cancer Res. 1984; 44(12 Pt 1):5757-63. View

BAXTER R . Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand Suppl. 1991; 372:107-14; discussion 115. DOI: 10.1111/j.1651-2227.1991.tb17983.x. View

10.

Elgin R, Busby Jr W, Clemmons D . An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci U S A. 1987; 84(10):3254-8. PMC: 304847. DOI: 10.1073/pnas.84.10.3254. View

11.

Shimasaki S, Shimonaka M, Zhang H, Ling N . Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J Biol Chem. 1991; 266(16):10646-53. View

12.

Yee D, Cullen K, Paik S, Perdue J, Hampton B, Schwartz A . Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res. 1988; 48(23):6691-6. View

13.

Wood W, Cachianes G, Henzel W, Winslow G, Spencer S, Hellmiss R . Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein. Mol Endocrinol. 1988; 2(12):1176-85. DOI: 10.1210/mend-2-12-1176. View

14.

Sporn M, Roberts A, Roche N, Kagechika H, Shudo K . Mechanism of action of retinoids. J Am Acad Dermatol. 1986; 15(4 Pt 2):756-64. DOI: 10.1016/s0190-9622(86)70231-4. View

15.

Camacho-Hubner C, McCusker R, Clemmons D . Secretion and biological actions of insulin-like growth factor binding proteins in two human tumor-derived cell lines in vitro. J Cell Physiol. 1991; 148(2):281-9. DOI: 10.1002/jcp.1041480214. View

16.

BAXTER R, Martin J . Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res. 1989; 1(1):49-68. DOI: 10.1016/0955-2235(89)90041-0. View

17.

Clemmons D, Camacho-Hubner C, Coronado E, Osborne C . Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990; 127(6):2679-86. DOI: 10.1210/endo-127-6-2679. View

18.

Yee D, Paik S, Lebovic G, Marcus R, Favoni R, Cullen K . Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989; 3(3):509-17. DOI: 10.1210/mend-3-3-509. View

19.

Jones J, DErcole A, Camacho-Hubner C, Clemmons D . Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci U S A. 1991; 88(17):7481-5. PMC: 52324. DOI: 10.1073/pnas.88.17.7481. View

20.

Minuto F, Del Monte P, Barreca A, Nicolin A, Giordano G . Partial characterization of somatomedin C-like immunoreactivity secreted by breast cancer cells in vitro. Mol Cell Endocrinol. 1987; 54(2-3):179-84. DOI: 10.1016/0303-7207(87)90155-9. View